American Century Companies Inc. Sells 166,997 Shares of Danaher Corporation $DHR

Key Points

• American Century Companies Inc. decreased its stake in Danaher Corporation by 15.4%, selling 166,997 shares during the first quarter, bringing their total ownership to approximately 919,369 shares worth $188,471,000.
• Several institutional investors have increased their stakes in Danaher, with notable increases from Vanguard Group (up by 0.4%) and Capital World Investors (up by 32.7%).
• Danaher reported a quarterly EPS of $1.80, exceeding analyst expectations, with revenue of $5.94 billion representing a 3.4% increase year-over-year.

American Century Companies Inc. trimmed its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 15.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 919,369 shares of the conglomerate's stock after selling 166,997 shares during the quarter. American Century Companies Inc. owned about 0.13% of Danaher worth $188,471,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Nuveen LLC acquired a new stake in shares of Danaher in the first quarter valued at about $833,941,000. GAMMA Investing LLC grew its position in shares of Danaher by 24,958.2% in the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock valued at $383,524,000 after purchasing an additional 1,863,381 shares during the last quarter. Two Sigma Advisers LP grew its position in shares of Danaher by 4,248.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock valued at $376,347,000 after purchasing an additional 1,601,800 shares during the last quarter. Capital World Investors grew its position in shares of Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock valued at $1,460,215,000 after purchasing an additional 1,566,658 shares during the last quarter. Finally, Invesco Ltd. grew its position in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

NYSE DHR traded down $4.15 during trading on Thursday, reaching $207.25. 847,494 shares of the company traded hands, compared to its average volume of 4,213,817. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The stock's 50 day moving average price is $200.46 and its two-hundred day moving average price is $199.62. The company has a market cap of $148.40 billion, a price-to-earnings ratio of 44.04, a P/E/G ratio of 2.96 and a beta of 0.73. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company's quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft lowered their price target on Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Robert W. Baird raised their price target on Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research report on Friday, July 18th. HSBC lowered their price target on Danaher from $270.00 to $240.00 in a research report on Friday, April 25th. Leerink Partners lifted their target price on Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 23rd. Finally, UBS Group decreased their target price on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.